Corcept Stock Crashes 20% as Genmab's Rina-S Posts Landmark Phase 3 Results in Ovarian Cancer

Corcept stock fell 20.13% on Friday, October 23, 2026 — because a rival's drug just posted standout Phase 3 results in the exact cancer market Corcept entered this year.

Corcept Therapeutics (NASDAQ: CORT) closed at $85.86 on Friday, down $21.64 (-20.13%) from $107.50, after Genmab announced that its drug rinatabart sesutecan — known as Rina-S — met both its primary and key secondary endpoints in a Phase 3 trial in platinum-resistant ovarian cancer. That is the same patient population targeted by Lifyorli, the Corcept drug approved by the FDA in March 2026 and on sale since April 1. Volume confirmed a genuine repricing: about 3.10 million Corcept shares changed hands, roughly four times its average volume of about 737,741 shares. The stock traded between $84.13 and $106.09 and edged up about 1.15% to $86.84 after hours.

What happened

Genmab announced on October 23, 2026, that the global Phase 3 RAINFOL-02 trial of Rina-S met its primary endpoint of progression-free survival and its key secondary endpoint of overall survival in platinum-resistant ovarian cancer, versus investigator's choice chemotherapy. Rina-S is an antibody-drug conjugate targeting folate receptor alpha (FRα) and delivering a topoisomerase I inhibitor payload. Crucially, the trial enrolled patients regardless of FRα expression level or prior treatment with mirvetuximab, making the potential patient pool broader than a biomarker-selected population.

The numbers were unusually strong for this hard-to-treat setting. In the intent-to-treat population of 584 patients, Rina-S reduced the risk of disease progression or death by 71% (hazard ratio 0.29; p<0.0001) and the risk of death by 57% (hazard ratio 0.43; p<0.0001). In the primary analysis set of 492 patients, the reductions were 67% for progression or death (HR 0.33) and 56% for death (HR 0.44). Genmab said the safety profile was consistent with what was already known about Rina-S, with no new safety signals, and that full data will be submitted for presentation at a future medical meeting and discussed with regulators worldwide.

Why it's blowing up

Corcept's growth story has increasingly rested on Lifyorli. The drug — relacorilant, a selective glucocorticoid receptor antagonist, combined with nab-paclitaxel — was approved for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received one to three prior regimens. It generated $47.6 million in Q2 2026, its first quarter on the market, out of total net product revenue of $256.1 million, while Corcept's established hypercortisolism products, led by Korlym, contributed $208.6 million. Investors had been paying up for Lifyorli to reduce Corcept's dependence on Korlym — which is exactly why a strong competing entrant in the same indication landed so hard.

Coverage was blunt about the link. Seeking Alpha reported that Corcept sank 20% after Genmab announced positive Phase 3 results for a competing drug in platinum-resistant ovarian cancer, presenting new competitive pressure for Lifyorli. Industry coverage described the Genmab readout as a landmark result. Friday was not about anything Corcept did wrong that day — it was the market repricing how much of the ovarian cancer opportunity Corcept keeps if Rina-S reaches the market with data this strong.

Key facts

Corcept's close: $85.86, down $21.64 (-20.13%) on Friday, October 23, 2026, on about 3.10 million shares — roughly four times average volume.
The catalyst: Genmab's Phase 3 RAINFOL-02 trial of Rina-S met its progression-free survival primary endpoint and its overall survival key secondary endpoint in platinum-resistant ovarian cancer.
The headline data: 71% reduction in the risk of progression or death (HR 0.29) and 57% reduction in the risk of death (HR 0.43) in the 584-patient intent-to-treat population, both p<0.0001.
What's at stake: Lifyorli, approved in March 2026 and launched April 1, produced $47.6 million in Q2 2026 sales and is central to diversifying revenue beyond Korlym.
Safety: Genmab reported no new safety signals for Rina-S in the topline results.

What's next

Two things will decide whether Friday's drop was an overreaction or the start of a longer repricing. First, the full RAINFOL-02 data: Genmab plans to present complete results at a future medical meeting and discuss them with regulators, and the details — including performance across FRα expression levels — will shape how directly Rina-S competes with Lifyorli's label. Second, Corcept's own execution: Lifyorli is already approved and selling, it recently received a positive European CHMP opinion with a European Commission decision expected in Q4 2026, and Corcept's next earnings will show whether early launch momentum is holding. Friday's market message was clear either way: in platinum-resistant ovarian cancer, Corcept no longer gets valued as if it has the field to itself. This post reports what happened and why markets reacted; it is not financial advice.

Sources

FAQ

Why did Corcept (CORT) stock fall 20% on October 23, 2026?

Corcept fell 20.13% to $85.86 after Genmab reported positive Phase 3 results for Rina-S, a competing drug in platinum-resistant ovarian cancer — the market Corcept's Lifyorli entered in 2026.

What did Genmab's Rina-S trial show?

The Phase 3 RAINFOL-02 trial met its primary progression-free survival endpoint and its overall survival endpoint, cutting the risk of progression or death by 71% and the risk of death by 57% versus chemotherapy in the intent-to-treat population.

What is Lifyorli and when was it approved?

Lifyorli is Corcept's relacorilant combined with nab-paclitaxel, approved by the FDA in March 2026 for platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer; it generated $47.6 million in Q2 2026, its first quarter on sale.

Is Rina-S approved yet?

No. Rina-S is still investigational; Genmab said it will present the full data at a future medical meeting and discuss the results with regulators worldwide.